The Neuropharmacology of Ropinirole and Pramipexole in Parkinson's disease Treatment: From Receptors to response.

Kunal Jain; Shwetakumari Sharma; Trupti Patil; Mrunal Pendharkar

doi:10.36948/ijfmr.2026.v08i03.82099

The Neuropharmacology of Ropinirole and Pramipexole in Parkinson's disease Treatment: From Receptors to response.

Author(s)	Mr. Kunal Jain, Ms. Shwetakumari Sharma, Ms. Trupti Patil, Mrs. Mrunal Pendharkar
Country	India
Abstract	The treatment of Parkinson's disease (PD), a neurodegenerative condition marked by the death of dopaminergic neurons in the brain, heavily relies on neuropharmacology. In the treatment of Parkinson's disease (PD), dopaminergic agonists like ropinirole and pramipexole have become important pharmacological medicines. Both medications work by activating dopamine receptors in the brain, making up for the lower dopamine levels linked to Parkinson's disease. Pramipexole targets both D2-like and D3 receptors, which contributes to its therapeutic effects, whereas ropinirole is a selective D2-like receptor agonist. In early-stage Parkinson's disease (PD), these drugs are usually used as monotherapy; in later stages, they are used as supplements to levodopa treatment. Neuropharmacologically, by improving dopaminergic transmission, ropinirole and pramipexole can reduce motor symptoms such bradykinesia, stiffness, and tremors. Additionally, because they affect other neurotransmitter systems like serotonin, they may help manage non-motor symptoms including sadness and exhaustion. However, there are drawbacks to using these drugs, such as adverse effects including orthostatic hypotension, hallucinations, and impulse control issues. The goal of ongoing research is to maximize the practical use of these dopaminergic agonists in the treatment of Parkinson's disease (PD) and get a better understanding of their long-term consequences. In the context of Parkinson's disease, this abstract examines the neuropharmacological characteristics, therapeutic functions, and clinical implications of ropinirole and pramipexole. It focuses on their effects on dopaminergic signaling and their potential to alleviate the disease's motor and non-motor symptoms.
Keywords	Neuropharmacology, Dopaminergic Agonists, Ropinirole, Pramipexole, Parkinson’s Disease (PD), Dopamine Receptors, D2-like Receptors, D3 Receptors, Motor Symptoms, Non-motor Symptoms.
Field	Medical / Pharmacy
Published In	Volume 8, Issue 3, May-June 2026
Published On	2026-06-21
DOI	https://doi.org/10.36948/ijfmr.2026.v08i03.82099

View / Download PDF File

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

The Neuropharmacology of Ropinirole and Pramipexole in Parkinson's disease Treatment: From Receptors to response.

Share this